What antibiotics are recommended for treating acute pyelonephritis?

Antibiotic Treatment for Acute Pyelonephritis

For outpatient treatment of acute pyelonephritis, oral ciprofloxacin 500 mg twice daily for 7 days is the first-line choice when local fluoroquinolone resistance is ≤10%, while patients requiring hospitalization should receive intravenous fluoroquinolones, aminoglycosides with or without ampicillin, extended-spectrum cephalosporins/penicillins, or carbapenems based on local resistance patterns. 1

Critical First Step: Always Obtain Cultures

• Urine culture and susceptibility testing must be performed in all suspected pyelonephritis cases before initiating empirical therapy 1
• Tailor initial empirical therapy based on the infecting uropathogen once results are available 1
• Blood cultures should be reserved for immunocompromised patients, uncertain diagnoses, or suspected hematogenous infections 2

Outpatient Oral Therapy (Mild-to-Moderate Cases)

First-Line: Fluoroquinolones (when resistance ≤10%)

• Ciprofloxacin 500 mg twice daily for 7 days (with or without initial 400 mg IV dose) 1
• Ciprofloxacin 1000 mg extended-release once daily for 7 days 1
• Levofloxacin 750 mg once daily for 5 days 1

Critical caveat: If local fluoroquinolone resistance exceeds 10%, add an initial one-time IV dose of ceftriaxone 1 g or a consolidated 24-hour aminoglycoside dose 1

Alternative: Trimethoprim-Sulfamethoxazole

• TMP-SMX 160/800 mg (double-strength) twice daily for 14 days - only if the uropathogen is known to be susceptible 1
• If susceptibility is unknown, give initial IV ceftriaxone 1 g or aminoglycoside dose 1

Second-Line: Oral Cephalosporins (Less Effective)

• Cefpodoxime 200 mg twice daily for 10 days 1
• Ceftibuten 400 mg once daily for 10 days 1
• Oral β-lactams are less effective than fluoroquinolones or TMP-SMX 1
• Always give initial IV ceftriaxone 1 g or aminoglycoside if using oral β-lactams 1
• Duration should be 10-14 days for β-lactam therapy 1

Recent evidence suggests oral cephalosporins may have comparable UTI recurrence rates to first-line agents (16% vs 17%, p=0.851), challenging older data about inferior efficacy 3

Inpatient IV Therapy (Severe Cases or Hospitalization Required)

Indications for Hospitalization

• Complicated infections, sepsis, persistent vomiting, failed outpatient treatment, extremes of age 1, 2
• Immunocompromised status, pregnancy, diabetes, anatomic abnormalities, urolithiasis 1, 2

IV Antibiotic Options

Fluoroquinolones:

• Ciprofloxacin 400 mg twice daily 1
• Levofloxacin 750 mg once daily 1

Extended-Spectrum Cephalosporins:

• Ceftriaxone 1-2 g once daily (lower dose studied, higher recommended) 1
• Cefotaxime 2 g three times daily 1
• Cefepime 1-2 g twice daily 1

Aminoglycosides:

• Gentamicin 5 mg/kg once daily 1
• Amikacin 15 mg/kg once daily 1
• Should be combined with ampicillin, not used as monotherapy 1

Extended-Spectrum Penicillins:

• Piperacillin/tazobactam 2.5-4.5 g three times daily 1

Carbapenems (reserve for multidrug-resistant organisms):

• Imipenem/cilastatin 0.5 g three times daily 1
• Meropenem 1 g three times daily 1
• Only use when early culture results indicate multidrug-resistant organisms 1

Novel Agents for Resistant Organisms:

• Ceftolozane/tazobactam 1.5 g three times daily 1
• Ceftazidime/avibactam 2.5 g three times daily 1
• Cefiderocol 2 g three times daily 1
• Meropenem-vaborbactam 2 g three times daily 1
• Cefepime + enmetazobactam showed significantly higher efficacy versus carbapenems in network meta-analysis 4

Key Resistance Considerations

• E. coli causes 75-95% of uncomplicated pyelonephritis 1
• Fluoroquinolone resistance varies geographically but was <10% in most North America/Europe regions as of guideline publication 1
• Amoxicillin/ampicillin monotherapy should never be used empirically due to high resistance rates worldwide 1
• Extended-spectrum beta-lactamase (ESBL) producing E. coli prevalence is rising: 1% (2005) to 10% (2012) in French hospitals 5
• In ICU settings with obstructive pyelonephritis, ESBL organisms were found in 11% of cases 6

Common Pitfalls to Avoid

1. Using fluoroquinolones when local resistance >10% without initial IV long-acting agent 1
2. Prescribing oral β-lactams without initial IV ceftriaxone or aminoglycoside 1
3. Using TMP-SMX empirically without knowing susceptibility 1
4. Treating with amoxicillin or ampicillin monotherapy 1
5. Failing to obtain urine cultures before starting antibiotics 1
6. Not adjusting therapy based on culture results 1

Duration of Therapy

• Fluoroquinolones: 5-7 days 1
• TMP-SMX: 14 days 1
• Oral β-lactams: 10-14 days 1

Follow-Up

• Repeat urine culture 1-2 weeks after completing antibiotic therapy 2
• If no response after 72 hours, obtain repeat cultures and consider imaging (CT scan) to rule out obstruction or abscess 1
• Independent risk factors for UTI recurrence include chronic kidney disease and Klebsiella species isolation 3